Agenda

All times displayed for Europe/Berlin timezone.

Pharma Insight Briefings

Trends in Sustainable pharma Packaging & Drug Delivery Devices
10:30 - 11:40 110D50
InnoPack & P-MEC Theatre
Managing Director
Pharmacentric Solutions
Sustainability and Strategic Innovation Director
Huhtamaki Flexible Packaging
Research & Innovation Manager
Berry Global
Eco-Design Manager
Adelphe

Sponsored by:

[In collaboration with Pharmapack Europe]
With an increased focus on sustainability throughout the supply chain, Packaging companies face a key challenge in developing innovative solutions with a reduced environmental impact - without compromising the safety, security and efficacy of drug products. This panel will assess the latest trends and developments in the sustainable packaging space.

Advances in Polymers for Container Closure Systems
11:50 - 12:20 110D50
InnoPack & P-MEC Theatre
Global Market Development Team Leader
Honeywell

Sponsored by:

Demand for polymer-based container closure systems for the drug delivery of both new chemical entities (NCEs) and new active substances (NASs) have been growing for more than 40 years. As Pharma continues to invest in new therapies whilst employing new mechanisms of actions it is today harder than ever before to demonstrate that a proposed packaging system is suitable for its intended use. Containers for drug products should be composed of materials that are considered safe for use with the dosage form and the route of administration. They should adequately protect the dosage form and should be compatible with it. This seminar highlights recent advances in polymer-based high barrier bottles, vials and bags. Special emphasis is made on Honeywell’s efforts to minimizing: 1. Permeation of gases and liquids through polymers; 2. Migration of additives and oligomers from packaging into the drug product; 3. Penetration and absorption of active and non-active substances into packaging and 4. Protein binding on surfaces. Highlighted are further efforts to develop new polymers that withstand gamma-sterilization and cryogenic temperatures below – 190 °C.

The Future of Pharma Packaging – Developments, Trends and Solutions in Secondary Packaging
12:30 - 13:00 110D50
InnoPack & P-MEC Theatre
Head of Marketing and Innovation
August Faller

Sponsored by:

Some important challenges lay ahead the pharmaceutical industry. Time to Market, Total Cost of Ownership, Cost of Goods, Digitalization, Serialization … just to name a few.
August Faller wants to give you an exclusive insight into the latest developments, trends and solutions in pharma secondary packaging.
 
Focus on: 
 Compliance & Convenience > Smart Packaging provides new possibilities
 Increased regulatory demands > Tamper Evidence Solutions and Serialization
 Flexibility > Launch Services and Digital Printing Solutions boost your Time to Market (TTM)
 Supply Chain Integration > intelligent ways to decrease Total Cost of Ownership (TCO)
Target:
As a long-time and very experienced specialist in secondary pharma packaging - we´d like to give you an exclusive insight into the latest development in the market and future possibilities. With pleasure we want to share our know-how with you, give food for thoughts and good ideas that create real benefits for you.
 
Target group:
Decision makers in the pharmaceutical and health care industry, persons responsible for and/or interested in the field of secondary packaging. 
 This comprises areas like development, marketing, packaging, distribution and purchasing.

Implementing aseptic filling with Ready-to-Use molded glass vials
13:10 - 13:40 110D50
InnoPack & P-MEC Theatre
Marketing Analyst
SGD Pharma

Sponsored by:

The introduction of Sterinity by SGD Pharma (Paris, France), a global leader of molded glass packaging, makes the manufacture of RTU molded glass vials commercially accessible for the first time. Powered by the well-established EZ Fill® platform from Ompi (Padua, Italy) this new product extends the commercial and practical benefits of RTU to a widest range of applications.
The Sterinity offer provides an ‘off-the-shelf’ solution for aseptic filling, producing RTU molded glass vials suitably packaged for streamlined, final ‘fill and finish’ processing in a range of proprietary filling technology. Sterinity is leveraging the advantages of Ompi EZ-fill® secondary packaging, that has been already tested and adopted in a wide range of fill-finish equipment platforms.
Vials are produced and 100% inspected in a clean room environment at the SGD Pharma plant, then washed with WFI, depyrogenized, packed and sterilized by ethylene oxide. Packed and sealed, RTU glass vials can be stored, with 5 years shelf life, and/or transported, ready for use as required.
The Sterinity offer uses molded glass vials made from Type I glass of exemplary quality. A steadily expanding portfolio of products in a range of sizes will be commercialized over the next one to two years, focusing on two core designs: a premium quality ISO design and an optimized EasyLyo® product. Both types of vial are currently available for use in tray format; nest and tub configurations are currently in development.
Sterinity boasts a diverse glass vial portfolio that meets all industry standards and customer requirements. As the need for flexible filling increases, companies will be seeking a cost-effective quality solution to streamline production and increase the speed of changeover. As the first commercial solution for RTU molded glass, SGD Pharma’s Sterinity platform is a viable answer to this pressing issue.

Innovative system Guarders® - integrated solution  for monitoring and assessing baby’s  health during the first 18 months
13:50 - 14:20 110D50
InnoPack & P-MEC Theatre
Project Medical Scientific Advisor
Palma Group

Sponsored by:

Latest Data of OXYCAPT Multilayer Plastic Vial & Syringe
14:30 - 15:00 110D50
InnoPack & P-MEC Theatre
Research Manager
Mitsubishi Gas Chemical Company

Sponsored by:

OXYCAPT is multilayer plastic vial & syringe. The three-layered structure achieves excellent oxygen barrier, water vapour barrier, ultraviolet barrier, very low extractables, low protein adsorption, high break resistance, etc. In addition to some basic data such as oxygen barrier, water vapour barrier, organic and inorganic extractables and ultraviolet barrier, we will show some latest data like oxidation of antibody, resistance to lyophilization, cold storage and liquid nitrogen storage, protein aggregation and container closure integrity.

High viscosity/high volume drugs - Challenges and needs for shorter needles and integrated systems
15:10 - 15:40 110D50
InnoPack & P-MEC Theatre
Global Marketing Manager
Becton Dickinson & Co

Sponsored by:

There is an increasing trend of biologic drug pipeline development in the chronic disease space being formulated with high viscosity and/or higher volume. In order to dispense safer, more effective and less painful injections in the subcutaneous layer, needle solutions including shorter needles might become the ultimate solution to improve quality of life and delivery outcomes of chronic disease patients. To further improve chronic patient adherence to treatment, autoinjector solutions are proven to be a preferred choice. Therefore, a robust performing device is necessary to increase the chances of adherence and effective drug delivery by patients. To optimize system integration of combination products, it is necessary to master the engineering process to bring the different systems cooperating together in one performing system. BD has developed deep domain knowledge to support the development of more robust, well-designed systems such as its new BD Intevia™ Platform.

Measuring the value of improved workflow efficiency and safety of drug administration with prefilled syringes
15:50 - 16:00 110D50
InnoPack & P-MEC Theatre
Acute Care Portfolio Manager
Becton Dickinson & Co

Sponsored by:

Understanding hospital and care center’s unmet needs is vital for providing them with impactful solutions. In the healthcare setting, patient safety concerns exist across the entire drug delivery spectrum. Specifically, in an acute care setting where decisions are often made quickly or under stress, error rates can be at their highest. Here we will discuss how differences in primary container options for injectable drugs can add value by offering care centers configurations that address universal pain points.

Mucoadhesive tablets.
16:30 - 17:00 110D50
InnoPack & P-MEC Theatre
Co-Founder & BD manager
Tree of Life

Sponsored by: